Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020


Technology Review: Gene Editing

Technology Review: Gene Editing

Edition one of Phacilitate's technology review series examines gene editing approaches by viral and non-viral methods and where to access these services

phacilitate technology review series one advanced therapies gene editing

The manipulation of DNA and specific gene editing is one of the great scientific breakthroughs of our time. However, delivering gene modifying material into cells has posed some challenges, particularly when it comes to the large amounts required for advanced therapies and their required doses.

This report focuses on the various methods of delivery, their relative advantages and disadvantages, as well as the companies that are offering them.



Read more to understand:

  • Who’s offering non-viral approaches to cell engineering and how they are disrupting the cell membrane
  • The key characteristics and qualities of the four main vector types
  • A review of the organisations providing viral vectors for clinical and commercial needs

See the report here

phacilitate exchange technology review gene editing phacilitate leaders europe
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd